BACKGROUND & AIMS: A balance between effector and regulatory T-cell (Treg) responses is required to maintain intestinal homeostasis. To regulate immunity, T cells migrate to the intestine using a combination of adhesion molecules and chemokine receptors. However, it is not known whether the migration pathways of effector cells and Tregs are distinct or shared. We sought to determine whether interaction between the chemokine receptor 9 (CCR9) and its ligand, chemokine ligand 25 (CCL25), allows effectors or Tregs to localize to chronically inflamed small intestine. METHODS: By using a mouse model that develops Crohn's-like ileitis (tumor necrosis factor Δadenosine uracyl-rich element [TNFΔARE] mice) we examined the role of CCL25-CCR9 interactions for effector and Treg traffic using flow cytometry, quantitative reverse-transcription polymerase chain reaction, immunohistochemistry, immunoneutralization, and proliferation analyses. RESULTS: In TNFΔARE mice, expression of CCL25 and the frequency of CCR9-expressing lymphocytes increased during late-stage disease. In the absence of CCR9, TNFΔARE mice developed exacerbated disease, compared with their CCR9-sufficient counterparts, which coincided with a deficiency of CD4(+)/CD25(+)/forkhead box P3(+) and CD8(+)/CD103(+) Tregs within the intestinal lamina propria and mesenteric lymph nodes. Furthermore, the CD8(+)/CCR9(+) subset decreased the proliferation of CD4(+) T cells in vitro. Administration of a monoclonal antibody against CCR9 to TNFΔARE mice exacerbated ileitis in vivo, confirming the regulatory role of CD8(+)/CCR9(+) cells. CONCLUSIONS: Signaling of the chemokine CCL25 through its receptor CCR9 induces Tregs to migrate to the intestine. These findings raise concerns about the development of reagents to disrupt this pathway for the treatment of patients with Crohn's disease.
BACKGROUND & AIMS: A balance between effector and regulatory T-cell (Treg) responses is required to maintain intestinal homeostasis. To regulate immunity, T cells migrate to the intestine using a combination of adhesion molecules and chemokine receptors. However, it is not known whether the migration pathways of effector cells and Tregs are distinct or shared. We sought to determine whether interaction between the chemokine receptor 9 (CCR9) and its ligand, chemokine ligand 25 (CCL25), allows effectors or Tregs to localize to chronically inflamed small intestine. METHODS: By using a mouse model that develops Crohn's-like ileitis (tumor necrosis factor Δadenosine uracyl-rich element [TNFΔARE] mice) we examined the role of CCL25-CCR9 interactions for effector and Treg traffic using flow cytometry, quantitative reverse-transcription polymerase chain reaction, immunohistochemistry, immunoneutralization, and proliferation analyses. RESULTS: In TNFΔARE mice, expression of CCL25 and the frequency of CCR9-expressing lymphocytes increased during late-stage disease. In the absence of CCR9, TNFΔARE mice developed exacerbated disease, compared with their CCR9-sufficient counterparts, which coincided with a deficiency of CD4(+)/CD25(+)/forkhead box P3(+) and CD8(+)/CD103(+) Tregs within the intestinal lamina propria and mesenteric lymph nodes. Furthermore, the CD8(+)/CCR9(+) subset decreased the proliferation of CD4(+) T cells in vitro. Administration of a monoclonal antibody against CCR9 to TNFΔARE mice exacerbated ileitis in vivo, confirming the regulatory role of CD8(+)/CCR9(+) cells. CONCLUSIONS: Signaling of the chemokine CCL25 through its receptor CCR9 induces Tregs to migrate to the intestine. These findings raise concerns about the development of reagents to disrupt this pathway for the treatment of patients with Crohn's disease.
Authors: Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn Journal: Gastroenterology Date: 2007-03-21 Impact factor: 22.682
Authors: E J Kunkel; J J Campbell; G Haraldsen; J Pan; J Boisvert; A I Roberts; E C Ebert; M A Vierra; S B Goodman; M C Genovese; A J Wardlaw; H B Greenberg; C M Parker; E C Butcher; D P Andrew; W W Agace Journal: J Exp Med Date: 2000-09-04 Impact factor: 14.307
Authors: Eóin N McNamee; Joanne C Masterson; Marisol Veny; Colm B Collins; Paul Jedlicka; Fergus R Byrne; Gordon Y Ng; Jesús Rivera-Nieves Journal: J Leukoc Biol Date: 2015-01-30 Impact factor: 4.962
Authors: Mohammad Salem; Caroline Wallace; Maria Velegraki; Anqi Li; Ephraim Ansa-Addo; Alessandra Metelli; Hyunwoo Kwon; Brian Riesenberg; Bill Wu; Yongliang Zhang; Silvia Guglietta; Shaoli Sun; Bei Liu; Zihai Li Journal: Cancer Res Date: 2019-01-23 Impact factor: 12.701
Authors: Marc-André Wurbel; Severine Le Bras; Mouna Ibourk; Michael Pardo; Maria G McIntire; Dominique Coco; Raif S Geha; Edda Fiebiger; Scott B Snapper Journal: Inflamm Bowel Dis Date: 2014-07 Impact factor: 5.325
Authors: Karin Fransén; Petra Franzén; Anders Magnuson; Ali Ateia Elmabsout; Nils Nyhlin; Anna Wickbom; Bengt Curman; Leif Törkvist; Mauro D'Amato; Johan Bohr; Curt Tysk; Allan Sirsjö; Jonas Halfvarson Journal: PLoS One Date: 2013-08-19 Impact factor: 3.240